Berberine displays antitumor activity in esophageal cancer cells in vitro.
Berberine treatment resulted in growth inhibition of KYSE-70 and SKGT4 cells in a dose-dependent and time-dependent manner.
Esophageal Cancer · LIVING RESEARCH LIBRARY
Ongoing Research for Esophageal Cancer Using Advanced Alternative Medicine
Explore positive published findings by substance, cancer biology, treatment interaction and quality-of-life outcome.
Every entry includes the original study title, year, concise finding and a direct PubMed link.
Call 1.800.923.7878Ask About Your Esophageal Cancer Case
Tell us the diagnosis, stage, biomarkers, current treatment plan and research questions you want to understand. Our Patient Care Team will follow up personally.
Prefer to speak now?
Call 1.800.923.7878
Living research library · positive published findingsOpen study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed →
Research organized by substance and finding
Browse 17 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked substance to move directly to its corresponding Sunridge page.
Open study on PubMed →
Curcumin inhibits esophageal squamous cell carcinoma progression through down-regulating the circNRIP1/miR-532-3p/AKT pathway.
Additionally, ESCC cells exposed to 20 μM of curcumin exhibited significantly decreased proliferative and invasive capacities, as well as enhanced cell apoptosis.
Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells.
In contrast to concerns that curcuminoids taken by patients through diet or diet supplements might interfere with chemotherapy, suppression of 5-FU efficacy by curcumin was not observed.
Inhibition of glutathione metabolism attenuates esophageal cancer progression.
In addition, treatment with L-buthionine-sulfoximine (BSO) to deplete glutathione decreased the ESCC tumor burden in mice, thus demonstrating the critical role of glutathione metabolism in ESCC progression.
Dysbiosis of gut microbiota in patients with esophageal cancer.
At the genus level, a significantly increased abundance of Streptococcus, Bifidobacterium, Subdoligranulum, Blautia, Romboutsia, Collinsella, Paeniclostridium, Dorea, and Atopobium were observed in EC patients, while Lachnospira, Bacteroides, Agathobacter, Lachnoclostridium, Parabacteroides, Paraprevotella, Butyricicoccus, Tyzzerella, Fusicatenibacter, and Sutterella were reduced.
Esophageal microbiome correlates with post-esophagectomy anastomotic leak in cancer patients.
Despite continuous improvement in long-term survival after esophagectomy, potential serious post-operative complications, such as anastomotic leaks (ALs), still occur.
Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.
Recent evidence suggests that modulation of the intestinal microbiota may influence the therapeutic response to ICIs.
Fungal microbiota signatures anticipate neoadjuvant immunochemotherapy outcomes in esophageal cancer.
Predicting neoadjuvant immunochemotherapy (NICT) response remains a critical challenge in esophageal squamous cell carcinoma (ESCC) management.
Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma.
The microbiomes of patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity.
Multi-omics analysis reveals microbiome-associated subtypes of esophageal cancer with distinct immune profiles and therapeutic responses.
This multi-omics analysis reveals esophageal cancer's molecular heterogeneity and identifies microbiome and immune signatures associated with prognosis and therapeutic response, providing a framework for developing personalized treatments targeting specific subtypes.
Probiotic-derived ferrichrome induces DDIT3-mediated antitumor effects in esophageal cancer cells.
Previously, we demonstrated that ferrichrome, produced by the probiotic Lactobacillus casei, exhibited anti-tumor effects in various gastrointestinal cancers, including colorectal and gastric cancers, with minimal effects on non-cancerous intestinal cells.
Relationship Between the Oral Microbiome and Treatment Efficacy in Esophageal Squamous Cell Carcinoma.
Alpha diversity of the oral microbiota was significantly correlated with the pathological response.
The oral microbiome is associated with the diagnosis, prognosis and radiotherapy sensitivity of esophageal cancer.
After radiotherapy, the oral microbial diversity and richness were significantly reduced.
Valeric acid from oral microbiome suppresses esophageal cancer growth by disrupting eEF1A1 -mediated translational output.
Surprisingly, we find that the oral microbiota derived from ESCC patients-not that from healthy controls-exhibits potent inhibitory and cytotoxic effects on ESCC cells.
Quercetin inhibits invasion and angiogenesis of esophageal cancer cells.
The migration distance and the number of invasive cells were significantly reduced in the 10 μg/mL quercetin group.
[Retracted] Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer.
The study reports [Retracted] Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer.
Resveratrol induces apoptosis in human esophageal carcinoma cells.
Immunohistochemical staining showed that after the treatment of EC-9706 cells with resveratrol (10 mmol/L) for 24 to 96 hours, the PRs of Bcl-2 proteins were apparently reduced with treated time (P<0.05) and the PRs of Bax proteins were apparently increased with treated time (P<0.05).
No studies match those filters. Clear a filter or try a broader term.